Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Diagnosis
52 results:
1. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract] [Full Text] [Related]
2. IMMUNOREACT 7: Regular aspirin use is associated with immune surveillance activation in colorectal cancer.
Simoni O; Scarpa M; Castagliuolo I; Stepanyan A; Angriman I; Kotsafti A; Nacci C; Scognamiglio F; Negro S; D'Angelo A; Chiminazzo V; Businello G; Ruffolo C; Salmaso R; Franzato B; Gruppo M; Pilati P; Scapinello A; Pozza A; Stecca T; Massani M; Cataldo I; Brignola S; Dei Tos AP; Ceccon C; Guzzardo V; Vignotto C; Facci L; Maretto I; Agostini M; Marchegiani F; Becherucci G; Zizzo M; Bordignon G; Merenda R; Pirozzolo G; Recordare A; Pozza G; Godina M; Mondi I; Verdi D; Lio CD; Laurino L; Saadeh L; Rivella G; Guerriero S; Romiti C; Portale G; Cipollari C; Spolverato YC; Noaro G; Cola R; Candioli S; Gavagna L; Ricagna F; Ortenzi M; Guerrieri M; Tagliente G; Tomassi M; Tedeschi U; Salmaso B; Buzzi G; Parini D; Prando D; Zuin M; Bergamo F; Zagonel V; Porzionato A; Cavallin F; Camillo BD; Cristoforo LD; Bao QR; Pucciarelli S; Bardini R; Spolverato G; Fassan M; Scarpa M;
Cancer; 2024 Jul; 130(13):2272-2286. PubMed ID: 38644692
[TBL] [Abstract] [Full Text] [Related]
3. [Expression of immune checkpoints pd-l1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract] [Full Text] [Related]
4. Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.
Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
[TBL] [Abstract] [Full Text] [Related]
5. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
6. Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target.
Huang X; Zhang W; Yang N; Zhang Y; Qin T; Ruan H; Zhang Y; Tian C; Mo X; Tang W; Liu J; Zhang B
Mol Cancer; 2024 Jan; 23(1):19. PubMed ID: 38243263
[TBL] [Abstract] [Full Text] [Related]
7. The expression of UNC5D is abnormal in the early stage of colorectal tumors associated with its proliferation and migration.
Shi LP; Zou C; Mao LJ; Chen TT; Xie T
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):199-213. PubMed ID: 38235871
[TBL] [Abstract] [Full Text] [Related]
8. Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy.
Cheng S; Han Z; Dai D; Li F; Zhang X; Lu M; Lu Z; Wang X; Zhou J; Li J; Guo X; Song P; Qiu C; Shen W; Zhang Q; Zhu N; Wang X; Tan Y; Kou Y; Yin X; Shen L; Peng Z
Cell Rep Med; 2024 Jan; 5(1):101355. PubMed ID: 38194971
[TBL] [Abstract] [Full Text] [Related]
9. PFKP is a prospective prognostic, diagnostic, immunological and drug sensitivity predictor across pan-cancer.
Peng J; Li P; Li Y; Quan J; Yao Y; Duan J; Liu X; Li H; Yuan D; Wang X
Sci Rep; 2023 Oct; 13(1):17399. PubMed ID: 37833332
[TBL] [Abstract] [Full Text] [Related]
10. CHSY1 promotes CD8
Sun G; Zhao S; Fan Z; Wang Y; Liu H; Cao H; Sun G; Huang T; Cai H; Pan H; Rong D; Gao Y; Tang W
J Exp Clin Cancer Res; 2023 Sep; 42(1):248. PubMed ID: 37749638
[TBL] [Abstract] [Full Text] [Related]
11. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.
Mishima S; Naito Y; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
Int J Clin Oncol; 2023 Oct; 28(10):1237-1258. PubMed ID: 37599324
[TBL] [Abstract] [Full Text] [Related]
12. Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability-Lessons from colorectal cancer.
Greco L; Rubbino F; Dal Buono A; Laghi L
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372349
[TBL] [Abstract] [Full Text] [Related]
13. Circular RNA hsa_circ_0064559 affects tumor cell growth and progression of colorectal cancer.
Zhen Y; Sun G; Chen C; Li J; Xiao R; Xu Z
World J Surg Oncol; 2023 Jun; 21(1):171. PubMed ID: 37280630
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic significances of pd-l1- and CTLA-4-positive T cells and positive correlations of immunosuppressive marker expression between cancer tissue and peripheral blood in patients with gastric cancer.
Lee KH; Kim SJ; Woo JS; Lee SY; Jhun J; Moon J; Jung YJ; Cho ML; Song KY
Front Immunol; 2023; 14():1138743. PubMed ID: 37153541
[TBL] [Abstract] [Full Text] [Related]
15. [Clinicopathological characteristics of gastric SMARCA4-deficient undifferentiated/rhabdoid carcinoma].
Wu JY; Jiang K; Yan LJ; Yin LS; Huang XZ; Jia L; Sun Y
Zhonghua Bing Li Xue Za Zhi; 2023 May; 52(5):447-453. PubMed ID: 37106285
[No Abstract] [Full Text] [Related]
16. Influence of location-dependent sex difference on pd-l1, MMR/MSI, and EGFR in colorectal carcinogenesis.
Choi J; Kim N; Nam RH; Kim JW; Song CH; Na HY; Kang GH
PLoS One; 2023; 18(2):e0282017. PubMed ID: 36802389
[TBL] [Abstract] [Full Text] [Related]
17. Deficient mismatch repair/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract] [Full Text] [Related]
18. Microsatellite instability/mismatch repair deficiency and activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland: A case report.
Yang G
Medicine (Baltimore); 2022 Aug; 101(34):e30311. PubMed ID: 36042639
[TBL] [Abstract] [Full Text] [Related]
19. Roles of circulating tumor DNA in PD-1/pd-l1 immune checkpoint Inhibitors: Current evidence and future directions.
Liu Z; Han Y; Dang Q; Xu H; Zhang Y; Duo M; Lv J; Li H; Kong Y; Han X
Int Immunopharmacol; 2022 Oct; 111():109173. PubMed ID: 35998502
[TBL] [Abstract] [Full Text] [Related]
20. pd-l1 Expression in colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition.
Secinti IE; Ozgur T; Dede I
Am J Clin Pathol; 2022 Oct; 158(4):506-515. PubMed ID: 35938631
[TBL] [Abstract] [Full Text] [Related]
[Next]
